Peptide therapy TikTok claims: what the science actually supports

What did @thenulevelteam actually say?

The creator promoted a product called "Somarland" as their top peptide pick for women of all ages, describing it as something that makes you "sleep better, feel stronger, have more energy" and will "for sure help you feel younger." They compared it loosely to CJC-1295 and ipamorelin, said it has "been around the longest" with the most patient feedback, and noted women specifically report the most positive results. The video ended with a pitch for a free provider consultation and a customized diet plan included with treatment.

To be direct: this video is a product promotion with a thin scientific veneer. The creator acknowledged bias once, briefly, then spent the rest of the clip in sales mode.

Does the science back this up?

The underlying biology of growth hormone secretagogues is real. The certainty attached to a specific branded product is not.

CJC-1295 is a synthetic GHRH analog shown to stimulate GH release. A 2006 study by Ionescu and Frohman in Growth Hormone and IGF Research confirmed dose-dependent GH secretion in healthy adults. Ipamorelin, a ghrelin mimetic, shows a cleaner side-effect profile than older GH secretagogues and has supportive data in preclinical and early human work. So the general category has a real evidence base. Sleep quality improvements and modest body composition changes are plausible outcomes for some patients on these compounds.

But "Somarland" is a branded compounded formulation, not a drug with its own peer-reviewed trial data. Saying it "does something similar to CJC-1295 or ipamorelin" probably means it contains one or both, but the creator never confirms the formulation. You cannot transplant clinical data from studied peptides onto a proprietary blend with unknown ratios, excipients, or sourcing quality.

What did they get wrong (or right)?

The mechanism is directionally correct. The certainty is completely unjustified.

"For sure help you feel younger" is a sales line, not a scientific finding. No compounded peptide blend has cleared a clinical threshold that would support that language. A 2019 review by Walker in Drugs and Aging noted that GH secretagogues show promise for body composition and vitality markers, but evidence in older women specifically is limited and long-term safety data are sparse. Effect sizes in the literature are modest and vary substantially by individual.

The claim that Somarland has "been around the longest" is unverifiable. Compounded formulation brands are not tracked in any public registry that would allow that comparison. Brand age is not a proxy for evidence quality.

Credit where it is due: directing users to a provider consultation before starting is appropriate. Pairing any GH axis intervention with nutritional guidance is also consistent with legitimate clinical practice.

What should you actually know?

If you are considering growth hormone secretagogue therapy, this video skips the questions that actually matter.

• Women have naturally higher GH pulse frequency than men. A 2010 paper by Veldhuis et al. in Journal of Clinical Endocrinology and Metabolism documented sex-specific differences in GH regulation with direct implications for how these therapies behave in female patients.
• Compounded peptides occupy a complicated regulatory space. The FDA has flagged CJC-1295 as ineligible for traditional compounding under 503A and 503B frameworks. Quality control varies significantly across pharmacies.
• "Patients love it" collected by the company selling the product is the lowest evidentiary tier available. Positive anecdotes from a self-selected, commercially motivated sample tell you almost nothing about whether you will respond the same way.
• Any intervention affecting the GH axis warrants baseline labs and follow-up monitoring, including IGF-1, fasting glucose, and in some cases lipid panels. A free consultation is a starting point, not a substitute for that workup.